Cargando…
Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age*
SUMMARY: BACKGROUND: Plaque psoriasis has a relatively high prevalence in adolescence, resulting in a significant impact on quality of life, including social interactions. OBJECTIVES: The primary objective was to assess the safety of once-daily application of fixed-combination calcipotriol plus beta...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298245/ https://www.ncbi.nlm.nih.gov/pubmed/24980277 http://dx.doi.org/10.1111/bjd.13235 |
_version_ | 1782353241954058240 |
---|---|
author | Gooderham, M Debarre, J-M Keddy-Grant, J Xu, Z Kurvits, M Goodfield, M |
author_facet | Gooderham, M Debarre, J-M Keddy-Grant, J Xu, Z Kurvits, M Goodfield, M |
author_sort | Gooderham, M |
collection | PubMed |
description | SUMMARY: BACKGROUND: Plaque psoriasis has a relatively high prevalence in adolescence, resulting in a significant impact on quality of life, including social interactions. OBJECTIVES: The primary objective was to assess the safety of once-daily application of fixed-combination calcipotriol plus betamethasone dipropionate gel in adolescent scalp psoriasis. Assessment of efficacy was a secondary objective. METHODS: This phase II, multicentre, single-arm, open-label, 8-week trial included patients aged 12–17 years with moderate-to-very severe scalp psoriasis according to Investigator's Global Assessment (IGA) (≥ 10% of the scalp area affected). RESULTS: Seventy-eight patients received treatment. Twenty-seven patients (35%) reported a total of 64 adverse events (AEs); most were mild (33/64) or moderate (22/64) in severity and there were no serious AEs. No cases of hypercalcaemia were reported, and the mean changes from baseline to end of treatment in albumin-corrected serum calcium (0·00 mmol L(−1)), 24-h urinary calcium excretion (−0·03 mmol per 24 h) and urinary calcium-to-creatinine ratio (−0·12 mmol g(−1)) were not considered clinically relevant. At the end of treatment 66 patients (85%) were clear or almost clear according to IGA. There was an 80% improvement in mean Total Sign Score from baseline to end of treatment. In total, at the end of treatment, 87% of patients rated their scalp psoriasis as clear or very mild, and 75 (96%) had no or mild pruritus compared with 14 (18%) at baseline. CONCLUSIONS: Once-daily calcipotriol plus betamethasone dipropionate gel is well tolerated and efficacious for scalp psoriasis in adolescents. WHAT'S ALREADY KNOWN ABOUT THIS TOPIC? Calcipotriol plus betamethasone dipropionate gel is a well-tolerated and efficacious treatment for scalp and body psoriasis in adults. . Psoriasis can present during childhood or adolescence and may negatively impact quality of life. . WHAT DOES THIS STUDY ADD? Calcipotriol plus betamethasone dipropionate gel is well tolerated and shows efficacy for treatment of scalp psoriasis in an adolescent population. . |
format | Online Article Text |
id | pubmed-4298245 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BlackWell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-42982452015-01-27 Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age* Gooderham, M Debarre, J-M Keddy-Grant, J Xu, Z Kurvits, M Goodfield, M Br J Dermatol Original Articles SUMMARY: BACKGROUND: Plaque psoriasis has a relatively high prevalence in adolescence, resulting in a significant impact on quality of life, including social interactions. OBJECTIVES: The primary objective was to assess the safety of once-daily application of fixed-combination calcipotriol plus betamethasone dipropionate gel in adolescent scalp psoriasis. Assessment of efficacy was a secondary objective. METHODS: This phase II, multicentre, single-arm, open-label, 8-week trial included patients aged 12–17 years with moderate-to-very severe scalp psoriasis according to Investigator's Global Assessment (IGA) (≥ 10% of the scalp area affected). RESULTS: Seventy-eight patients received treatment. Twenty-seven patients (35%) reported a total of 64 adverse events (AEs); most were mild (33/64) or moderate (22/64) in severity and there were no serious AEs. No cases of hypercalcaemia were reported, and the mean changes from baseline to end of treatment in albumin-corrected serum calcium (0·00 mmol L(−1)), 24-h urinary calcium excretion (−0·03 mmol per 24 h) and urinary calcium-to-creatinine ratio (−0·12 mmol g(−1)) were not considered clinically relevant. At the end of treatment 66 patients (85%) were clear or almost clear according to IGA. There was an 80% improvement in mean Total Sign Score from baseline to end of treatment. In total, at the end of treatment, 87% of patients rated their scalp psoriasis as clear or very mild, and 75 (96%) had no or mild pruritus compared with 14 (18%) at baseline. CONCLUSIONS: Once-daily calcipotriol plus betamethasone dipropionate gel is well tolerated and efficacious for scalp psoriasis in adolescents. WHAT'S ALREADY KNOWN ABOUT THIS TOPIC? Calcipotriol plus betamethasone dipropionate gel is a well-tolerated and efficacious treatment for scalp and body psoriasis in adults. . Psoriasis can present during childhood or adolescence and may negatively impact quality of life. . WHAT DOES THIS STUDY ADD? Calcipotriol plus betamethasone dipropionate gel is well tolerated and shows efficacy for treatment of scalp psoriasis in an adolescent population. . BlackWell Publishing Ltd 2014-12 2014-10-22 /pmc/articles/PMC4298245/ /pubmed/24980277 http://dx.doi.org/10.1111/bjd.13235 Text en © 2014 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Gooderham, M Debarre, J-M Keddy-Grant, J Xu, Z Kurvits, M Goodfield, M Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age* |
title | Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age* |
title_full | Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age* |
title_fullStr | Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age* |
title_full_unstemmed | Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age* |
title_short | Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age* |
title_sort | safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age* |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298245/ https://www.ncbi.nlm.nih.gov/pubmed/24980277 http://dx.doi.org/10.1111/bjd.13235 |
work_keys_str_mv | AT gooderhamm safetyandefficacyofcalcipotriolplusbetamethasonedipropionategelinthetreatmentofscalppsoriasisinadolescents1217yearsofage AT debarrejm safetyandefficacyofcalcipotriolplusbetamethasonedipropionategelinthetreatmentofscalppsoriasisinadolescents1217yearsofage AT keddygrantj safetyandefficacyofcalcipotriolplusbetamethasonedipropionategelinthetreatmentofscalppsoriasisinadolescents1217yearsofage AT xuz safetyandefficacyofcalcipotriolplusbetamethasonedipropionategelinthetreatmentofscalppsoriasisinadolescents1217yearsofage AT kurvitsm safetyandefficacyofcalcipotriolplusbetamethasonedipropionategelinthetreatmentofscalppsoriasisinadolescents1217yearsofage AT goodfieldm safetyandefficacyofcalcipotriolplusbetamethasonedipropionategelinthetreatmentofscalppsoriasisinadolescents1217yearsofage |